FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 530 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... April 9, 2024 Can Cancer Prevention Be Better Integrated into Primary Care? June 5, 2023 Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... October 19, 2020 That Cancer Conversation is back! April 19, 2023 Load more HOT NEWS Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment Cancer and Climate Change: The Health Threats of Unnatural Disasters GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... Coronavirus reports – Part 10: “I didn’t see my mum before...
